Načítá se...
Doxorubicin and cyclophosphamide for the treatment of canine lymphoma: a randomized, placebo-controlled study
Median survival times (STs) for doxorubicin-treated canine lymphoma range from 5.7 to 9 months. Because dogs treated with multi-agent protocols have longer STs, we sought to evaluate whether adding cyclophosphamide would improve outcome in canine lymphoma patients while maintaining an acceptable lev...
Uloženo v:
| Hlavní autoři: | , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2010
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3129606/ https://ncbi.nlm.nih.gov/pubmed/20691026 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1476-5829.2010.00215.x |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|